

# CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

**Most recent changes to the CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes Long Descriptor document:**

- Removal of FDA approval pending symbol (↯) from codes 90380 and 90381.
- Correct “Revised Code Effective” date from May 1, 2023 to April 18, 2023 for code 0164A.

\*For the purposes of CPT coding, “Immunization” includes vaccines/toxoids, immune globulins, serum or recombinant products.

It is important to note that further CPT Editorial Panel or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions” may result in gaps in code number sequencing.

**The removal of the FDA pending symbol follows notification that this product had been granted FDA approval status on the date indicated. Code 90678 was originally published in CPT 2023.**

Codes	Long Descriptor	Released to AMA Website	FDA Approval Effective	Publication
↯90678	Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use	June 30, 2023	May 31, 2023	CPT <sup>®</sup> 2024

**The following vaccine codes were accepted at the July 2022 CPT Editorial Panel meeting for the 2024 CPT production cycle. These codes are effective immediately on July 26, 2022.**

**\*Note that code 90611 will follow code 90713 and code 90622 will follow code 90627.**

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
#●90611	Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use	July 26, 2022	July 26, 2022	CPT <sup>®</sup> 2024
#●90622	Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use	July 26, 2022	July 26, 2022	CPT <sup>®</sup> 2024

**The following vaccine codes were accepted at the February 2023 CPT Editorial Panel meeting for the 2024 CPT production cycle. Code 90679 was effective immediately on May 3, 2023. Codes 90589, 90623 are effective on January 1, 2024.**

**\*Note that code 90589 will follow code 90586 and code 90623 will follow 90619.**

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
#↯●90589	Chikungunya virus vaccine, live attenuated, for intramuscular use	June 30, 2023	January 1, 2024	CPT <sup>®</sup> 2024
#↯●90623	Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use	June 30, 2023	January 1, 2024	CPT <sup>®</sup> 2024



## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

●90679	Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use	May 5, 2023	May 3, 2023	CPT <sup>®</sup> 2024
--------	--	-------------	-------------	-----------------------

The following immunization codes were accepted at the May 2023 CPT Editorial Panel meeting for the 2024 CPT production cycle. Codes 90380, 90381 was effective immediately on July 17, 2023. Code 90683 is effective on January 1, 2024.

\*Note that code 90683 will follow code 90679.

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
✕●90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	June 30, 2023	July 17, 2023	CPT <sup>®</sup> 2024
✕●90381	1 mL dosage, for intramuscular use	June 30, 2023	July 17, 2023	CPT <sup>®</sup> 2024
#✕●90683	Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use	June 30, 2023	January 1, 2024	CPT <sup>®</sup> 2024

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

The following codes were accepted by the CPT Editorial Panel. Codes 0001A, 0002A, and 91300 are effective December 11, 2020. Codes 0011A, 0012A, and 91301 are effective December 18, 2020. Codes 0031A and 91303 are effective February 27, 2021. Revised code 0031A is effective October 20, 2021. Codes 0003A and 0013A are effective August 12, 2021. Code 0004A is effective on September 22, 2021. Codes 0034A, 0064A, and 91306 are effective October 20, 2021. Codes 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 91305, and 91307 are effective October 29, 2021. Code 0073A is effective January 3, 2022. Codes 0094A and 91309 are effective March 29, 2022. Code 0074A is effective May 17, 2022. Codes 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0111A, 0112A, 0113A, 91308, and 91311 are effective June 17, 2022. Revised code 0094A is effective July 6, 2022. Codes 0041A, 0042A, and 91304 are effective July 13, 2022. Codes 0124A and 91312 are effective August 31, 2022. Codes 0134A and 91313 are effective August 31, 2022 for patient aged 18 years and older. Codes 0134A (12 years through 17 years), 0144A, 0154A, 91313 (12 years through 17 years), 91314, and 91315 are effective October 12, 2022. Code 0044A is effective October 19, 2022. Codes 0164A, 0173A, 91316, and 91317 are effective December 8, 2022. Revised code 0173A and new code 0174A are effective March 14, 2023. Revised codes 0124A, 0134A, 0144A, 0154A, 0164A, 0173A, 0174A and new codes 0121A, 0141A, 0142A, 0151A, 0171A, 0172A are effective April 18, 2023.

Codes 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A, 91300, 91301, 91305, 91306, 91307, 91308, 91309, and 91311 are no longer authorized for use in the United States as of April 18, 2023.

Codes 0031A, 0034A, and 91303 are no longer authorized for use in the United States as of June 1, 2023.

Codes 0021A, 0022A, 0104A, 91302, and 91310 will be effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration.

\*Note codes 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0104A, 0111A, 0112A, 0113A, and resequenced codes 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A will follow code 90474. Resequenced codes 91300, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309, 91310, 91311, 91312, 91313, 91314, 91315, 91316 and 91317 will precede code 90476.

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
	<p><b>Evaluation and Management Preventive Medicine Services</b></p> <p>► Vaccine/toxoid products, immunization administrations, ancillary studies involving laboratory, radiology, other procedures, or screening tests (eg, vision, hearing, developmental) identified with a specific CPT code are reported separately. For immunization administration and vaccine risk/benefit counseling, see 90460, 90461, 90471-90474, 0001A, 0002A, <del>0003A, 0004A,</del> 0011A, 0012A, <del>0013A,</del> 0021A, 0022A, 0031A, <del>0034A,</del> 0041A, 0042A, <del>0044A,</del> 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A. For vaccine/toxoid products, see 90476-90759, 91300-<del>91317</del><del>91316</del><del>91315</del><del>91314</del><del>91313</del><del>91312</del><del>91311</del><del>91310</del>, 91301, 91302, 91303, <del>91304,</del> <del>91305,</del> <del>91306,</del> <del>91307,</del> <del>91308,</del> <del>91309.</del> ◀</p>	<p><b>Revised Guidelines Released to AMA Website</b></p> <p>November 10, 2020</p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>March 1, 2021</p> <p>May 4, 2021</p> <p>July 30, 2021</p> <p>August 16, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p> <p>October 27, 2021</p> <p>January 12, 2022</p>	<p><b>New and Revised Guidelines Effective</b></p> <p><del>0071A, 0072A,</del> <del>91305, 91307,</del> <del>October 29, 2021</del></p> <p><del>0073A: January 3,</del> <del>2022</del></p> <p><del>0094A, 91309:</del> <del>March 29, 2022</del></p> <p><del>0074A: May 17, 2022</del></p> <p><del>0081A, 0082A,</del> <del>0083A, 0091A,</del> <del>0092A, 0093A,</del> <del>0111A, 0112A,</del> <del>0113A, 91308,</del> <del>91311:</del> <del>June 17, 2022</del></p> <p>0041A, 0042A, 91304:</p>	<p><b>New and Revised Guidelines Publication</b></p> <p>CPT<sup>®</sup> 2022/2023/2024</p>



# CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

		February 1, 2022 March 7, 2022 April 26, 2022 May 19, 2022 June 7, 2022 July 6, 2022 August 31, 2022 October 10, 2022 November 16, 2022 December 9, 2022 March 17, 2023 May 1, 2023	July 13, 2022 0124A, 0134A (18 years and older): August 31, 2022 0134A (12 years through 17 years), 0144A, 0154A, 91315: October 12, 2022 0044A: October 19, 2022 0164A, 0173A, 91316, 91317: December 8, 2022 0174A: March 14, 2023 0121A, 0141A, 0142A, 0151A, 0171A, 0172A: April 18, 2023 0021A, 0022A, 0104A, 91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	
	<p><b>Medicine Immunization Administration for Vaccines/Toxoids</b></p> <p>► Report vaccine immunization administration codes (90460, 90461, 90471-90474, 0001A, 0002A, <u>0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A</u>) in addition to the vaccine and toxoid code(s) (90476-90759, 91300-<del>91317</del><u>91316</u><del>91318-91319</del><u>91315</u><del>91320-91321</del><u>91311</u><del>91322-91323</del><u>91310</u><del>91324-91325</del><u>91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309</u>).</p> <p>Report codes 90460 and 90461 only when the physician or other qualified health care professional provides face-to-face counseling of the patient/family during the administration of a vaccine other than when performed for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccines. For immunization administration of any vaccine, other than</p>	<p><b>New and Revised Guidelines Released to AMA Website</b></p> <p>November 10, 2020          December 17, 2020          January 19, 2021          March 1, 2021          May 4, 2021          July 30, 2021          August 16, 2021          September 3, 2021</p>	<p><b>New and Revised Guidelines Effective</b></p> <p><del>0001A, 0002A, 91300-</del>  <del>December 11, 2020</del>  <del>0011A, 0012A, 91301-</del>  <del>December 18, 2020</del>          0031A, 91303: February 27, 2021  <del>0003A, 0013A:</del>  <del>August 12, 2021</del>  <del>0004A: September 22, 2021</del></p>	<p><b>New and Revised Guidelines Publication</b></p> <p>CPT<sup>®</sup> 2022/2023/2024</p>

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	<p>SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines, that is not accompanied by face-to-face physician or other qualified health care professional counseling to the patient/family/guardian or for administration of vaccines to patients over 18 years of age, report 90471-90474. (See also <b>Instructions for Use of the CPT Codebook</b> for definition of reporting qualifications.) ◀</p> <p>► Report <u>0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A</u> for immunization administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines only. Each administration code is specific to each individual vaccine product (eg, <del>91300-91317, 91316, 91315, 91311, 91310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309</del>), the dosage schedule (eg, first dose, second dose), and counseling, when performed. The appropriate administration code is chosen based on the type of vaccine and the specific dose number the patient receives in the schedule. For example, 0012A is reported for the second dose of vaccine 91301. Do not report 90460-90474 for the administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines. Codes related to SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine administration are listed in Appendix Q, with their associated vaccine code descriptors, vaccine administration codes, <u>patient age</u>, vaccine manufacturer, vaccine name(s), National Drug Code (NDC) Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code descriptor and must be the vaccine represented by the manufacturer and vaccine name listed in Appendix Q. ◀</p> <p>If a significant separately identifiable Evaluation and Management service (eg, new or established patient office or other outpatient services [99202-99215], office or other outpatient consultations [99242-99245], emergency department services [99281-99285], preventive medicine services [99381-99429]) is performed, the appropriate E/M service code should be reported in addition to the vaccine and toxoid administration codes.</p> <p>A component refers to all antigens in a vaccine that prevent disease(s) caused by one organism (90460 and 90461). Multi-valent antigens or multiple serotypes of antigens against a single organism are considered a single component of vaccines. Combination vaccines are those vaccines that contain multiple vaccine components. Conjugates or adjuvants contained in vaccines are not considered to be component parts of the vaccine as defined above.</p> <p style="padding-left: 40px;">(For allergy testing, see 95004 et seq)</p> <p style="padding-left: 40px;">(For skin testing of bacterial, viral, fungal extracts, see 86485-86580)</p>	<p>October 6, 2021</p> <p>October 27, 2021</p> <p>January 12, 2022</p> <p>February 1, 2022</p> <p>March 7, 2022</p> <p>April 26, 2022</p> <p>May 19, 2022</p> <p>June 7, 2022</p> <p>July 6, 2022</p> <p>August 31, 2022</p> <p>October 10, 2022</p> <p>November 16, 2022</p> <p>December 9, 2022</p> <p>March 17, 2023</p> <p>May 1, 2023</p>	<p><del>0034A, 0064A, 91306:</del> October 20, 2021</p> <p><del>0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 91305, 91307:</del> <del>October 29, 2021</del></p> <p><del>0073A:</del> January 3, 2022</p> <p><del>0094A, 91309:</del> <del>March 29, 2022</del></p> <p><del>0074A:</del> May 17, 2022</p> <p><del>0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0111A, 0112A, 0113A, 91308, 91311:</del> <del>June 17, 2022</del></p> <p>0041A, 0042A, 91304: July 13, 2022</p> <p>0124A, 0134A (18 years and older): August 31, 2022</p> <p>0134A (12 years through 17 years), 0144A, 0154A, 91315: October 12, 2022</p> <p>0044A: October 19, 2022</p> <p>0164A, 0173A, 91316, 91317: December 8, 2022</p> <p>0174A: March 14, 2023</p> <p>0121A, 0141A, 0142A, 0151A, 0171A, 0172A: April 18, 2023</p> <p>0021A, 0022A, 0104A, 91302, 91310: Effective upon receiving</p>	
--	--	--	---	--

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	(For therapeutic or diagnostic injections, see 96372-96379)		Emergency Use Authorization or approval from the Food and Drug Administration	
90460	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered			
✚90461	<p>each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)</p> <p>(Use 90460 for each vaccine administered. For vaccines with multiple components [combination vaccines], report 90460 in conjunction with 90461 for each additional component in a given vaccine)</p> <p>► (Do not report 90460, 90461 in conjunction with <del>91300-91317, 91316, 91315, 91311, 91310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309,</del> unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter) ◀</p>	<p><b>New Parenthetical Note Released to AMA Website</b></p> <p>November 10, 2020</p> <p><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>March 1, 2021</p> <p>May 4, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p> <p>February 1, 2022</p> <p>March 7, 2022</p> <p>April 26, 2022</p> <p>May 19, 2022</p> <p>August 31, 2022</p> <p>November 16, 2022</p> <p>December 9, 2022</p>	<p><b>New and Revised Parenthetical Note Effective</b></p> <p><del>91300: December 41, 2020</del></p> <p><del>91301: December 18, 2020</del></p> <p>91303: February 27, 2021</p> <p><del>91306: October 20, 2021</del></p> <p><del>91305, 91307: October 29, 2021</del></p> <p><del>91309: March 29, 2022</del></p> <p><del>91308, 91311: June 17, 2022</del></p> <p>91304: July 13, 2022</p> <p>91315: October 12, 2022</p> <p>91316, 91317: December 8, 2022</p> <p>91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	<p><b>New and Revised Parenthetical Note Publication</b></p> <p>CPT<sup>®</sup> 2022/2023/2024</p>
90471	<p>Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)</p> <p>(Do not report 90471 in conjunction with 90473)</p>			

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

<p><b>+90472</b></p>	<p>each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)</p> <p>(Use 90472 in conjunction with 90460, 90471, 90473)</p> <p>► (Do not report 90471, 90472 in conjunction with <del>91300, 91317, 91316, 91315, 91311, 91310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309</del>, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter) ◀</p> <p>(For immune globulins, see 90281-90399. For administration of immune globulins, see 96365, 96366, 96367, 96368, 96369, 96370, 96371, 96374)</p> <p>(For intravesical administration of BCG vaccine, see 51720, 90586)</p>	<p style="text-align: center;"><b>New Parenthetical Note Released to AMA Website</b></p> <p style="text-align: center;">November 10, 2020</p> <p style="text-align: center;"><b>Revised Parenthetical Note Released to AMA Website</b></p> <p style="text-align: center;">December 17, 2020</p> <p style="text-align: center;">January 19, 2021</p> <p style="text-align: center;">March 1, 2021</p> <p style="text-align: center;">May 4, 2021</p> <p style="text-align: center;">September 3, 2021</p> <p style="text-align: center;">October 6, 2021</p> <p style="text-align: center;">February 1, 2022</p> <p style="text-align: center;">March 7, 2022</p> <p style="text-align: center;">April 26, 2022</p> <p style="text-align: center;">May 19, 2022</p> <p style="text-align: center;">August 31, 2022</p> <p style="text-align: center;">November 16, 2022</p> <p style="text-align: center;">December 9, 2022</p>	<p style="text-align: center;"><b>New and Revised Parenthetical Note Effective</b></p> <p><del>91300: December 11, 2020</del></p> <p><del>91301: December 18, 2020</del></p> <p>91303: February 27, 2021</p> <p><del>91306: October 20, 2021</del></p> <p><del>91305, 91307: October 29, 2021</del></p> <p><del>91309: March 29, 2022</del></p> <p><del>91308, 91311: June 17, 2022</del></p> <p>91304: July 13, 2022</p> <p>91315: October 12, 2022</p> <p>91316, 91317: December 8, 2022</p> <p>91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	<p style="text-align: center;"><b>New and Revised Parenthetical Note Publication</b></p> <p style="text-align: center;">CPT<sup>®</sup> 2022/2023/2024</p>
<p>90473</p>	<p>Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid)</p> <p>(Do not report 90473 in conjunction with 90471)</p>			
<p><b>+90474</b></p>	<p>each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)</p> <p>(Use 90474 in conjunction with 90460, 90471, 90473)</p> <p>► (Do not report 90473, 90474 in conjunction with <del>91300, 91317, 91316, 91315, 91311, 91310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309</del>, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid</p>	<p style="text-align: center;"><b>New Parenthetical Note Released to AMA Website</b></p> <p style="text-align: center;">November 10, 2020</p> <p style="text-align: center;"><b>Revised Parenthetical Note Released to AMA Website</b></p>	<p style="text-align: center;"><b>New and Revised Parenthetical Note Effective</b></p> <p><del>91300: December 11, 2020</del></p> <p><del>91301: December 18, 2020</del></p> <p>91303: February 27, 2021</p>	<p style="text-align: center;"><b>New and Revised Parenthetical Note Publication</b></p> <p style="text-align: center;">CPT<sup>®</sup> 2022/2023/2024</p>

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter) ◀	<p>December 17, 2020</p> <p>January 19, 2021</p> <p>March 1, 2021</p> <p>May 4, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p> <p>February 1, 2022</p> <p>March 7, 2022</p> <p>April 26, 2022</p> <p>May 19, 2022</p> <p>August 31, 2022</p> <p>November 16, 2022</p> <p>December 9, 2022</p>	<p><del>91306: October 20, 2021</del></p> <p><del>91305, 91307: October 20, 2021</del></p> <p><del>91309: March 20, 2022</del></p> <p><del>91308, 91311: June 17, 2022</del></p> <p>91304: July 13, 2022</p> <p>91315: October 12, 2022</p> <p>91316, 91317: December 8, 2022</p> <p>91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	
●0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose	November 10, 2020	December 11, 2020	CPT <sup>®</sup> 2022
●0002A	second dose	November 10, 2020	December 11, 2020	CPT <sup>®</sup> 2022
●0003A	third dose	July 30, 2021	August 12, 2021	CPT <sup>®</sup> 2023
●0004A	booster dose ▶ (Report 0001A, 0002A, 0003A, 0004A for the administration of vaccine 91300) ◀	<p>September 3, 2021</p> <p>October 6, 2021</p> <p>February 1, 2022</p>	<p><del>0001A, 0002A, 91300: December 11, 2020</del></p>	CPT <sup>®</sup> 2022/2023/2024



## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	▶ (Do not report 0001A, 0002A, 0003A, 0004A in conjunction with 91305, 91307, 91308, 91312, 91315, 91317) ◀	August 31, 2022 December 9, 2022	<del>0003A: August 12, 2021</del> <del>0004A: September 22, 2021</del> <del>91305, 91307: October 29, 2021</del> <del>91308: June 17, 2022</del> 91312: August 31, 2022 91315: October 12, 2022 91317: December 8, 2022	
#●0051A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose	September 3, 2021	October 29, 2021 No longer authorized for use in the United States as of April 18, 2023	CPT <sup>®</sup> 2023
#●0052A	second dose	September 3, 2021	October 29, 2021 No longer authorized for use in the United States as of April 18, 2023	CPT <sup>®</sup> 2023
#●0053A	third dose	September 3, 2021	October 29, 2021 No longer authorized for use in the United States as of April 18, 2023	CPT <sup>®</sup> 2023
#●0054A	booster dose ▶ (Report 0051A, 0052A, 0053A, 0054A for the administration of vaccine 91305) ◀ ▶ (Do not report 0051A, 0052A, 0053A, 0054A in conjunction with 91300, 91307, 91308, 91312, 91315, 91317) ◀	September 3, 2021 February 1, 2022 August 31, 2022 December 9, 2022	<del>91300: December 11, 2020</del> <del>0051A, 0052A, 0053A, 0054A, 91305, 91307: October 29, 2021</del> <del>91308: June 17, 2022</del> 91312: August 31, 2022	CPT <sup>®</sup> 2023/2024

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

			<p>91315: October 12, 2022</p> <p>91317: December 8, 2022</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	
#●0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	May 1, 2023	April 18, 2023	CPT <sup>®</sup> 2024
#▲●0124A	<p><del>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster additional dose</del></p> <p>► (Report <u>0121A</u>, 0124A for the administration of vaccine 91312) ◀</p> <p>► (Do not report <u>0121A</u>, 0124A in conjunction with 91300, 91305, 91307, 91308, 91315, <u>91317</u>) ◀</p>	<p>August 31, 2022</p> <p>December 9, 2022</p> <p><b>Revised Code Released to AMA Website:</b></p> <p>May 1, 2023</p> <p><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>91300: December 11, 2020</del></p> <p><del>91305, 91307: October 29, 2021</del></p> <p><del>91308: June 17, 2022</del></p> <p>0124A, 91312: August 31, 2022</p> <p>91315: October 12, 2022</p> <p>91317: December 8, 2022</p> <p>0121A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p> <p><b>Revised Code Effective:</b></p> <p>April 18, 2023</p>	CPT <sup>®</sup> 2024
#●0071A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	October 6, 2021	<p>October 29, 2021</p> <p>No longer authorized for use in the United States as of April 18, 2023</p>	CPT <sup>®</sup> 2023

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

#●0072A	second dose	October 6, 2021	October 29, 2021 No longer authorized for use in the United States as of April 18, 2023	CPT <sup>®</sup> 2023
#●0073A	third dose	January 12, 2022	January 3, 2022 No longer authorized for use in the United States as of April 18, 2023	CPT <sup>®</sup> 2023
#●0074A	booster dose ► (Report 0071A, 0072A, <u>0073A</u> , <u>0074A</u> for the administration of vaccine 91307) ◀ ► (Do not report 0071A, 0072A, <u>0073A</u> , <u>0074A</u> in conjunction with 91300, 91305, <u>91308</u> , <u>91312</u> , <u>91315</u> , <u>91317</u> ) ◀	April 26, 2022 August 31, 2022 December 9, 2022	<del>91300: December 11, 2020</del> <del>0071A, 0072A, 91305: October 29, 2021</del> <del>0073A: January 3, 2022</del> <del>0074A: May 17, 2022</del> <del>91308: June 17, 2022</del> 91312: August 31, 2022 91315: October 12, 2022 91317: December 8, 2022  Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	CPT <sup>®</sup> 2023/2024
#●0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	May 1, 2023	April 18, 2023	CPT <sup>®</sup> 2024
#▲●0154A	<del>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2</del>	August 31, 2022 December 9, 2022	<del>91300: December 11, 2020</del> <del>91305, 91307:</del>	CPT <sup>®</sup> 2024

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	<p><del>mL dosage, diluent reconstituted, tris-sucrose formulation, booster additional dose</del></p> <p>► (Report <u>0151A</u>, 0154A for the administration of vaccine 91315) ◀</p> <p>► (Do not report <u>0151A</u>, 0154A in conjunction with 91300, 91305, 91307, 91308, 91312, <u>91317</u>) ◀</p>	<p><b>Revised Code Released to AMA Website:</b></p> <p>May 1, 2023</p> <p><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>October 29, 2021</del></p> <p><del>91308: June 17, 2022</del></p> <p>91312: August 31, 2022</p> <p>0154A, 91315: October 12, 2022</p> <p>91317: December 8, 2022</p> <p>0151A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p> <p><b>Revised Code Effective:</b></p> <p>April 18, 2023</p>	
#●0081A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	February 1, 2022	June 17, 2022 No longer authorized for use in the United States as of April 18, 2023	CPT <sup>®</sup> 2023
#●0082A	second dose	February 1, 2022	June 17, 2022 No longer authorized for use in the United States as of April 18, 2023	CPT <sup>®</sup> 2023
#●0083A	<p>third dose</p> <p>► (Report 0081A, 0082A, <u>0083A</u> for the administration of vaccine 91308) ◀</p> <p>► (Do not report 0081A, 0082A, <u>0083A</u> in conjunction with 91300, 91305, 91307, <u>91312</u>, <u>91315</u>, <u>91317</u>) ◀</p>	<p>June 7, 2022</p> <p>August 31, 2022</p> <p>December 9, 2022</p>	<p><del>91300: December 11, 2020</del></p> <p><del>91305, 91307: October 29, 2021</del></p> <p><del>0081A, 0082A, 0083A, 91308: June 17, 2022</del></p> <p>91312: August 31, 2022</p> <p>91315: October 12, 2022</p>	CPT <sup>®</sup> 2023/2024

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

			91317: December 8, 2022  Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
#●0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	May 1, 2023	April 18, 2023	CPT <sup>®</sup> 2024
#●0172A	second dose	May 1, 2023	April 18, 2023	CPT <sup>®</sup> 2024
#▲●0173A	<p><del>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose</del></p> <p>►(Report 0173A for the administration of vaccine 91317)◄</p> <p>►(Use 0173A in conjunction with 91317 only when used as a third dose administration of primary series for 91308, [ie, following administration of 0081A, 0082A])◄</p> <p>►(Do not report 0173A in conjunction with 91300, 91305, 91307, 91308, 91312, 91315)◄</p>	<p>December 9, 2022</p> <p><b>Revised Code Released to AMA Website:</b></p> <p>March 17, 2023</p> <p>May 1, 2023</p> <p><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>March 17, 2023</p>	<p><del>91300: December 11, 2020</del></p> <p><del>91305, 91307: October 29, 2021</del></p> <p><del>0081A, 0082A, 91308: June 17, 2022</del></p> <p>91312: August 31, 2022</p> <p>91315: October 12, 2022</p> <p>0173A, 91317: December 8, 2022</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p> <p><b>Revised Code Effective:</b></p> <p>March 14, 2023</p> <p>April 18, 2023</p>	CPT <sup>®</sup> 2024
#▲●0174A	<del>booster additional</del> dose	March 17, 2023	<del>91300: December 11, 2020</del>	CPT <sup>®</sup> 2024

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	<p>▶ (Report <u>0171A, 0172A, 0173A, 0174A</u> for the administration of vaccine 91317) ◀</p> <p>▶ (Use 0174A in conjunction with 91317 when used as <u>an additional</u> dose administration of primary series for 91308, [ie, following administration of 0081A, 0082A, 0083A]) ◀</p> <p>▶ (Do not report <u>0171A, 0172A, 0173A, 0174A</u> in conjunction with 91300, 91305, 91307, 91308, 91312, 91315) ◀</p>	<p><b>Revised Code Released to AMA Website:</b></p> <p>May 1, 2023</p> <p><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>91305, 91307: October 29, 2021</del></p> <p><del>0081A, 0082A, 0083A, 91308: June 17, 2022</del></p> <p>91312: August 31, 2022</p> <p>91315: October 12, 2022</p> <p>0173A, 91317: December 8, 2022</p> <p>0174A: March 14, 2023</p> <p>0171A, 0172A: April 18, 2023</p> <p><b>Revised Code Effective:</b></p> <p>April 18, 2023</p>	
●0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose	November 10, 2020	December 18, 2020 No longer authorized for use in the United States as of April 18, 2023	CPT <sup>®</sup> 2022
●0012A	second dose	November 10, 2020	December 18, 2020 No longer authorized for use in the United States as of April 18, 2023	CPT <sup>®</sup> 2022
●0013A	<p>third dose</p> <p>▶ (Report 0011A, 0012A, <u>0013A</u> for the administration of vaccine 91301) ◀</p> <p>▶ (Do not report 0011A, 0012A, 0013A in conjunction with <u>91306, 91309, 91311, 91313, 91314, 91316</u>) ◀</p>	<p>August 16, 2021</p> <p><b>New Parenthetical Note Released to AMA Website</b></p> <p>March 7, 2022</p> <p><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 19, 2022</p> <p>August 31, 2022</p> <p>November 16, 2022</p>	<p><del>0011A, 0012A, 91301: December 18, 2020</del></p> <p><del>0013A: August 12, 2021</del></p> <p><del>91306: October 20, 2021</del></p> <p><del>91309: March 29, 2022</del></p> <p>91311: June 17, 2022</p> <p>91313 (18 years and older): August 31, 2022</p>	CPT <sup>®</sup> 2023/2024

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

			<p>91313 (12 years through 17 years), 91314: October 12, 2022</p> <p>91316: December 8, 2022</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	
#●0064A	<p>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose</p> <p>▶ (Report 0064A for the administration of vaccine 91306) ◀</p> <p>▶ (Do not report 0064A in conjunction with 91301, 91309, 91311, 91313, 91314, 91316) ◀</p>	<p>September 3, 2021</p> <p><b>New Parenthetical Note Released to AMA Website</b></p> <p>March 7, 2022</p> <p><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 19, 2022</p> <p>August 31, 2022</p> <p>November 16, 2022</p>	<p><del>91301: December 18, 2020</del></p> <p><del>0064A, 91306: October 20, 2021</del></p> <p><del>91309: March 29, 2022</del></p> <p><del>91311: June 17, 2022</del></p> <p>91313 (18 years and older): August 31, 2022</p> <p>91313 (12 years through 17 years), 91314: October 12, 2022</p> <p>91316: December 8, 2022</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	CPT <sup>®</sup> 2023/2024
#▲●0134A	<p>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, <del>booster</del>-additional dose</p> <p>▶ (Report 0134A for the administration of vaccine 91313) ◀</p> <p>▶ (Do not report 0134A in conjunction with 91301, 91306, 91309, 91311, 91314, 91316) ◀</p>	<p>August 31, 2022</p> <p>November 16, 2022</p> <p><b>Revised Code Released to AMA Website:</b></p> <p>May 1, 2023</p>	<p><del>91301: December 18, 2020</del></p> <p><del>91306: October 20, 2021</del></p> <p><del>91309: March 29, 2022</del></p> <p><del>91311: June 17, 2022</del></p>	CPT <sup>®</sup> 2024

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

			<p>0134A and 91313 (18 years and older): August 31, 2022</p> <p>0134A and 91313 (12 years through 17 years), 91314: October 12, 2022</p> <p>91316: December 8, 2022</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p> <p><b>Revised Code Effective:</b></p> <p>April 18, 2023</p>	
#●0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	May 1, 2023	April 18, 2023	CPT <sup>®</sup> 2024
#●0142A	second dose	May 1, 2023	April 18, 2023	CPT <sup>®</sup> 2024
#▲●0144A	<p><del>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster additional dose</del></p> <p>► (Report <u>0141A, 0142A, 0144A</u> for the administration of vaccine 91314) ◀</p> <p>► (Do not report <u>0141A, 0142A, 0144A</u> in conjunction with 91301, 91306, 91309, 91311, 91313, <u>91316</u>) ◀</p>	<p>August 31, 2022 November 16, 2022</p> <p><b>Revised Code Released to AMA Website:</b></p> <p>May 1, 2023</p> <p><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>91301: December 18, 2020</del></p> <p><del>91306: October 20, 2021</del></p> <p><del>91309: March 29, 2022</del></p> <p><del>91311: June 17, 2022</del></p> <p>0144A, 91313 (12 years through 17 years), 91314: October 12, 2022</p> <p>91316: December 8, 2022</p> <p>0141A 0142A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are</p>	CPT <sup>®</sup> 2024



## CPT® Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

			no longer authorized for use in the United States as of April 18, 2023  <b>Revised Code Effective:</b>  April 18, 2023	
#●0091A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years	July 6, 2022	June 17, 2022  No longer authorized for use in the United States as of April 18, 2023	CPT® 2024
#●0092A	second dose, when administered to individuals 6 through 11 years	July 6, 2022	June 17, 2022  No longer authorized for use in the United States as of April 18, 2023	CPT® 2024
#●0093A	third dose, when administered to individuals 6 through 11 years	July 6, 2022	June 17, 2022  No longer authorized for use in the United States as of April 18, 2023	CPT® 2024
#▲●0094A	<p><del>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage booster dose, when administered to individuals 18 years and older</del></p> <p>► (Report <u>0091A, 0092A, 0093A, 0094A</u> for the administration of vaccine 91309) ◀</p> <p>► (Do not report <u>0091A, 0092A, 0093A, 0094A</u> in conjunction with <u>91301, 91306, 91311, 91313, 91314, 91316</u>) ◀</p>	<p><b>New Code Released to AMA Website:</b>  March 7, 2022</p> <p><b>Revised Parenthetical Note Released to AMA Website</b>  May 19, 2022  July 6, 2022  August 31, 2022  November 16, 2022</p> <p><b>Revised Code Released to AMA Website:</b>  July 6, 2022</p>	<p><del>91301: December 18, 2020</del></p> <p><del>91306: October 20, 2021</del></p> <p><del>91309: March 29, 2022</del></p> <p><b>New Code Effective:</b>  <del>0094A: March 29, 2022</del></p> <p><del>0091A, 0092A, 0093A, 91311: June 17, 2022</del></p> <p><b>Revised Code Effective:</b>  0094A: July 6, 2022</p> <p>91313 (18 years and older): August 31, 2022</p> <p>91313 (12 years through 17 years), 91314: October 12, 2022</p>	CPT® 2023/2024

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

			<p>91316: December 8, 2022</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	
●0021A	<p>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10<sup>10</sup> viral particles/0.5 mL dosage; first dose</p>	December 17, 2020	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2022
●0022A	<p style="text-align: center;">second dose</p> <p>► (Report 0021A, 0022A for the administration of vaccine 91302) ◀</p>	December 17, 2020	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2022
▲●0031A	<p>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10<sup>10</sup> viral particles/0.5 mL dosage; single dose</p>	<p><b>New Code Released to AMA Website:</b></p> <p>January 19, 2021</p> <p><b>Revised Code Released to AMA Website:</b></p> <p>October 27, 2021</p>	<p><b>New Code Effective:</b></p> <p>February 27, 2021</p> <p><b>Revised Code Effective:</b></p> <p>October 20, 2021</p> <p>No longer authorized for use in the United States as of June 1, 2023</p>	CPT <sup>®</sup> 2022/2023
●0034A	<p style="text-align: center;">booster dose</p> <p>► (Report 0031A, <u>0034A</u> for the administration of vaccine 91303) ◀</p>	October 27, 2021	<p>0031A, 91303: February 27, 2021</p> <p>0034A: October 20, 2021</p> <p>No longer authorized for use in the United States as of June 1, 2023</p>	CPT <sup>®</sup> 2023
●0041A	<p>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; first dose</p>	May 4, 2021	July 13, 2022	CPT <sup>®</sup> 2022

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

●0042A	second dose	May 4, 2021	July 13, 2022	CPT <sup>®</sup> 2022
●0044A	booster dose ▶ (Report 0041A, 0042A, <u>0044A</u> for the administration of vaccine 91304) ◀	October 10, 2022	October 19, 2022	CPT <sup>®</sup> 2024
●0104A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose ▶ (Report 0104A for the administration of vaccine 91310) ◀	April 26, 2022	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2023
●0111A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose	May 19, 2022	June 17, 2022 No longer authorized for use in the United States as of April 18, 2023	CPT <sup>®</sup> 2023
●0112A	second dose	May 19, 2022	June 17, 2022 No longer authorized for use in the United States as of April 18, 2023	CPT <sup>®</sup> 2023
●0113A	third dose ▶ (Report 0111A, 0112A, <u>0113A</u> for the administration of vaccine 91311) ◀ ▶ (Do not report 0111A, 0112A, <u>0113A</u> in conjunction with 91301, 91306, 91309, <u>91313, 91314, 91316</u> ) ◀	July 6, 2022 August 31, 2022 November 16, 2022	<del>91301: December 18, 2020</del> <del>91306: October 20, 2021</del> <del>91309: March 29, 2022</del> <del>0111A, 0112A, 0113A, 91311: June 17, 2022</del> 91313 (18 years and older): August 31, 2022 91313 (12 years through 17 years), 91314: October 12, 2022 91316: December 8, 2022  Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	CPT <sup>®</sup> 2023/2024

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

<p><b>▲●0164A</b></p>	<p>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, <del>booster</del> <u>additional dose</u></p> <p>▶ (Report 0164A for the administration of vaccine 91316) ◀</p> <p>▶ (Do not report 0164A in conjunction with 91301, 91306, 91309, 91311, 91313, 91314) ◀</p>	<p>November 16, 2022</p> <p><b>Revised Code Released to AMA Website:</b></p> <p>May 1, 2023</p>	<p><del>91301: December 18, 2020</del></p> <p><del>91306: October 20, 2021</del></p> <p><del>91309: March 29, 2022</del></p> <p><del>91311: June 17, 2022</del></p> <p>91313 (18 years and older): August 31, 2022</p> <p>91313 (12 years through 17 years), 91314: October 12, 2022</p> <p>0164A, 91316: December 8, 2022</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p> <p><b>Revised Code Effective:</b></p> <p>April 18, 2023 <del>May 1, 2023</del></p>	<p>CPT<sup>®</sup> 2024</p>
	<p><b>Vaccines, Toxoids</b></p> <p>To assist users to report the most recent new or revised vaccine product codes, the American Medical Association (AMA) currently uses the CPT website, which features updates of CPT Editorial Panel actions regarding these products. Once approved by the CPT Editorial Panel, these codes will be made available for release on a semiannual (twice a year: July 1 and January 1) basis. As part of the electronic distribution, there is a six-month implementation period from the initial release date (ie, codes released on January 1 are eligible for use on July 1 and codes released on July 1 are eligible for use January 1).</p>			

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	<p>The CPT Editorial Panel, in recognition of the public health interest in vaccine products, has chosen to publish new vaccine product codes prior to approval by the US Food and Drug Administration (FDA). These codes are indicated with the <i>✓</i> symbol and will be tracked by the AMA to monitor FDA approval status. Once the FDA status changes to approval, the <i>✓</i> symbol will be removed. CPT users should refer to the AMA CPT website (<a href="http://www.ama-assn.org/go/cpt-vaccine">www.ama-assn.org/go/cpt-vaccine</a>) for the most up-to-date information on codes with the <i>✓</i> symbol.</p>			
	<p>► Codes <del>90476-90759, 91300-91317, 91319, 91321, 91323, 91325, 91327, 91329, 91331, 91333, 91335, 91337, 91339, 91341, 91343, 91345, 91347, 91349, 91351, 91353, 91355, 91357, 91359, 91361, 91363, 91365, 91367, 91369, 91371, 91373, 91375, 91377, 91379, 91381, 91383, 91385, 91387, 91389, 91391, 91393, 91395, 91397, 91399</del> identify the vaccine product <b>only</b>. To report the administration of a vaccine/toxoid other than SARS-CoV-2 (coronavirus disease [COVID-19]), the vaccine/toxoid product codes (90476-90759) must be used in addition to an immunization administration code(s) (90460, 90461, 90471, 90472, 90473, 90474). To report the administration of a SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine, the vaccine/toxoid product codes (<del>91300-91317, 91319, 91321, 91323, 91325, 91327, 91329, 91331, 91333, 91335, 91337, 91339, 91341, 91343, 91345, 91347, 91349, 91351, 91353, 91355, 91357, 91359, 91361, 91363, 91365, 91367, 91369, 91371, 91373, 91375, 91377, 91379, 91381, 91383, 91385, 91387, 91389, 91391, 91393, 91395, 91397, 91399</del>) should be reported with the corresponding immunization administration codes (0001A, 0002A, <del>0003A, 0004A</del>, 0011A, 0012A, <del>0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A</del>). All SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, <u>patient age</u>, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code descriptor and must be the vaccine represented by the manufacturer and vaccine name listed in Appendix Q. ◀</p> <p>► Do not report 90476-90759 in conjunction with the SARS-CoV-2 (coronavirus disease [COVID-19]) immunization administration codes <del>0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A</del>, unless both a SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter. ◀</p> <p>► Modifier 51 should not be reported with vaccine/toxoid codes <del>90476-90759, 91300-91317, 91319, 91321, 91323, 91325, 91327, 91329, 91331, 91333, 91335, 91337, 91339, 91341, 91343, 91345, 91347, 91349, 91351, 91353, 91355, 91357, 91359, 91361, 91363, 91365, 91367, 91369, 91371, 91373, 91375, 91377, 91379, 91381, 91383, 91385, 91387, 91389, 91391, 91393, 91395, 91397, 91399</del> when reported in conjunction with administration codes 90460, 90461, 90471, 90472, 90473, 90474, 0001A, 0002A, <del>0003A, 0004A, 0011A, 0012A, 0013A, 0021A,</del></p>	<p><b>New and Revised Guidelines Released to AMA Website</b></p> <p>November 10, 2020</p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>March 1, 2021</p> <p>May 4, 2021</p> <p>July 30, 2021</p> <p>August 16, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p> <p>October 27, 2021</p> <p>January 12, 2022</p> <p>February 1, 2022</p> <p>March 7, 2022</p> <p>April 26, 2022</p> <p>May 19, 2022</p> <p>June 7, 2022</p> <p>July 6, 2022</p> <p>August 31, 2022</p> <p>October 10, 2022</p> <p>November 16, 2022</p>	<p><b>New and Revised Guidelines Effective</b></p> <p><del>0001A, 0002A, 91300-</del> December 11, 2020</p> <p><del>0011A, 0012A, 91301-</del> December 18, 2020</p> <p>0031A, 91303: February 27, 2021</p> <p><del>0003A, 0013A:</del> August 12, 2021</p> <p><del>0004A:</del> September 22, 2021</p> <p><del>0034A, 0064A, 91306:</del> October 20, 2021</p> <p><del>0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 91305, 91307:</del> October 29, 2021</p> <p><del>0073A:</del> January 3, 2022</p> <p><del>0094A, 91309:</del> March 29, 2022</p> <p><del>0074A:</del> May 17, 2022</p> <p><del>0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0111A, 0112A, 0113A, 91308, 91311:</del> June 17, 2022</p>	<p><b>New and Revised Guidelines Publication</b></p> <p>CPT<sup>®</sup> 2022/2023/2024</p>

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	<p>0022A, 0031A, <u>0034A</u>, 0041A, 0042A, <u>0044A</u>, <u>0051A</u>, <u>0052A</u>, <u>0053A</u>, <u>0054A</u>, <u>0064A</u>, <u>0071A</u>, <u>0072A</u>, <u>0073A</u>, <u>0074A</u>, <u>0081A</u>, <u>0082A</u>, <u>0083A</u>, <u>0091A</u>, <u>0092A</u>, <u>0093A</u>, <u>0094A</u>, <u>0104A</u>, <u>0111A</u>, <u>0112A</u>, <u>0113A</u>, <u>0121A</u>, <u>0124A</u>, <u>0134A</u>, <u>0141A</u>, <u>0142A</u>, <u>0144A</u>, <u>0151A</u>, <u>0154A</u>, <u>0164A</u>, <u>0171A</u>, <u>0172A</u>, <u>0173A</u>, <u>0174A</u>. ◀</p> <p>If a significantly separately identifiable Evaluation and Management (E/M) service (eg, office or other outpatient services, preventive medicine services) is performed, the appropriate E/M service code should be reported in addition to the vaccine and toxoid administration codes.</p> <p>To meet the reporting requirements of immunization registries, vaccine distribution programs, and reporting systems (eg, Vaccine Adverse Event Reporting System) the exact vaccine product administered needs to be reported. Multiple codes for a particular vaccine are provided in the CPT codebook when the schedule (number of doses or timing) differs for two or more products of the same vaccine type (eg, hepatitis A, Hib) or the vaccine product is available in more than one chemical formulation, dosage, or route of administration.</p>	<p>December 9, 2022</p> <p>March 17, 2023</p> <p>May 1, 2023</p>	<p>0041A, 0042A, 91304: July 13, 2022</p> <p>0124A, 0134A (18 years and older): August 31, 2022</p> <p>0134A (12 years through 17 years), 0144A, 0154A, 91315: October 12, 2022</p> <p>0044A: October 19, 2022</p> <p>0164A, 0173A, 91316, 91317: December 8, 2022</p> <p>0174A: March 14, 2023</p> <p>0121A, 0141A 0142A, 0151A, 0171A, 0172A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p> <p>0021A, 0022A, 0104A, 91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	
	<p>The “when administered to” age descriptions included in CPT vaccine codes are not intended to identify a product’s licensed age indication. The term “preservative free” includes use for vaccines that contain no preservative and vaccines that contain trace amounts of preservative agents that are not present in a sufficient concentration for the purpose of preserving the final vaccine formulation. The absence of a designation regarding a preservative does not necessarily indicate the presence or absence of preservative in the vaccine. Refer to the product’s prescribing information (PI) for the licensed age indication before administering vaccine to a patient.</p>	<p><b>New and Revised Guidelines Released to AMA Website</b></p> <p>November 10, 2020</p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>March 1, 2021</p>	<p><b>New and Revised Guidelines Effective</b></p> <p><del>91300: December 11, 2020</del></p> <p><del>91301: December 18, 2020</del></p> <p>91303: February 27, 2021</p> <p><del>0003A, 0013A:</del></p>	<p><b>New and Revised Guidelines Publication</b></p> <p>CPT<sup>®</sup> 2022/2023/2024</p>

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	<p>Separate codes are available for combination vaccines (eg, Hib-HepB, DTap-IPV/Hib). It is inappropriate to code each component of a combination vaccine separately. If a specific vaccine code is not available, the unlisted procedure code should be reported, until a new code becomes available.</p> <p>► The vaccine/toxoid abbreviations listed in codes 90476-90759, <del>91300-91317, 91316, 91315, 91314, 91310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309</del> reflect the most recent US vaccine abbreviation references used in the Advisory Committee on Immunization Practices (ACIP) recommendations at the time of CPT code set publication. Interim updates to vaccine code descriptors will be made following abbreviation approval by the ACIP on a timely basis via the AMA CPT website (<a href="http://ama-assn.org/cpt-cat-i-vaccine-codes">ama-assn.org/cpt-cat-i-vaccine-codes</a>). The accuracy of the ACIP vaccine abbreviation designations in the CPT code set does not affect the validity of the vaccine code and its reporting function.</p> <p><u>For the purposes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccinations, codes 0003A, 0013A, 0053A, 0073A, and 0083A, 0093A, and 0113A, and 0173A represent the administration of a third dose in the primary series (eg, patient with immunocompromising condition or patient age 6 months through 4 years) when the initial immune response following a two-dose primary vaccine series is likely to be insufficient (eg, immunocompromised patient). In contrast, the booster or additional dose codes 0004A, 0034A, 0044A, 0054A, and 0064A, 0074A, 0094A, and 0104A, 0124A, 0134A, 0144A, and 0154A, and 0164A, and 0174A represent the administration of a dose of vaccine when the initial immune response to a primary vaccine series was sufficient, but has likely waned over time. ◀</u></p> <p>(For immune globulins, see 90281-90399. For administration of immune globulins, see 96365-96375)</p>	<p>May 4, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p> <p>October 27, 2021</p> <p>January 12, 2022</p> <p>February 1, 2022</p> <p>March 7, 2022</p> <p>April 26, 2022</p> <p>May 19, 2022</p> <p>June 7, 2022</p> <p>July 6, 2022</p> <p>August 31, 2022</p> <p>October 10, 2022</p> <p>November 16, 2022</p> <p>December 9, 2022</p> <p>March 17, 2023</p> <p>May 1, 2023</p>	<p>August 12, 2021</p> <p><del>0004A: September 22, 2021</del></p> <p>0034A, 0064A, 91306:</p> <p>October 20, 2021</p> <p>0053A, 0054A, 91305, 91307:</p> <p><del>October 29, 2021</del></p> <p>0073A: <del>January 3, 2022</del></p> <p>0094A, 91309:</p> <p><del>March 29, 2022</del></p> <p>0074A: <del>May 17, 2022</del></p> <p>0083A, 0093A, 0113A, 91308,</p> <p>91311: <del>June 17, 2022</del></p> <p>91304: July 13, 2022</p> <p>0124A, 0134A (18 years and older):</p> <p>August 31, 2022</p> <p>0134A (12 years through 17 years), 0144A, 0154A, 91315:</p> <p>October 12, 2022</p> <p>0044A: October 19, 2022</p> <p>0164A, 0173A, 91316, 91317:</p> <p>December 8, 2022</p> <p>0174A: March 14, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p> <p>0104A, 91302, 91310: Effective upon receiving Emergency Use Authorization or</p>	
--	--	--	---	--

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

			approval from the Food and Drug Administration	
#●91300	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use</p> <p>▶ (Report 91300 with administration codes 0001A, 0002A, 0003A, 0004A) ◀</p> <p>▶ (Do not report 91300 in conjunction with administration codes 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0121A, 0124A, 0151A, 0154A, 0171A, 0172A, 0173A, 0174A) ◀</p>	<p><b>New Code Released to AMA Website:</b></p> <p>November 10, 2020</p> <p>July 30, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p> <p>January 12, 2022</p> <p>February 1, 2022</p> <p>April 26, 2022</p> <p>June 7, 2022</p> <p>August 31, 2022</p> <p>December 9, 2022</p> <p>March 17, 2023</p> <p><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>0001A, 0002A, 91300: December 11, 2020</del></p> <p><del>0003A: August 12, 2021</del></p> <p><del>0004A: September 22, 2021</del></p> <p><del>0051A, 0052A, 0053A, 0054A, 0071A, 0072A: October 29, 2021</del></p> <p><del>0073A: January 3, 2022</del></p> <p><del>0074A: May 17, 2022</del></p> <p><del>0081A, 0082A, 0083A: June 17, 2022</del></p> <p>0124A: August 31, 2022</p> <p>0154A: October 12, 2022</p> <p>0173A: December 8, 2022</p> <p>0174A: March 14, 2023</p> <p>0121A, 0151A, 0171A, 0172A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	CPT <sup>®</sup> 2022/2023/2024
#●91305	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use</p> <p>▶ (Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A) ◀</p>	<p>September 3, 2021</p> <p>October 6, 2021</p> <p>January 12, 2022</p> <p>February 1, 2022</p>	<p><del>0001A, 0002A: December 11, 2020</del></p> <p><del>0003A: August 12, 2021</del></p>	CPT <sup>®</sup> 2023/2024



## CPT® Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	<p>► (Do not report 91305 in conjunction with administration codes <u>0001A, 0002A, 0003A, 0004A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0121A, 0124A, 0151A, 0154A, 0171A, 0172A, 0173A, 0174A</u>) ◀</p>	<p>April 26, 2022</p> <p>June 7, 2022</p> <p>August 31, 2022</p> <p>December 09, 2022</p> <p>March 17, 2023</p> <p style="text-align: center;"><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>0004A: September 22, 2024</del></p> <p><del>0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 91305: October 29, 2024</del></p> <p><del>0073A: January 3, 2022</del></p> <p><del>0074A: May 17, 2022</del></p> <p><del>0081A, 0082A, 0083A: June 17, 2022</del></p> <p>0124A: August 31, 2022</p> <p>0154A: October 12, 2022</p> <p>0173A: December 8, 2022</p> <p>0174A: March 14, 2023</p> <p>0121A, 0151A, 0171A, 0172A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	
<p>#●91312</p>	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use</p> <p>► (Report 91312 with administration codes <u>0121A, 0124A</u>) ◀</p> <p>► (Do not report 91312 in conjunction with administration codes <u>0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0151A, 0154A, 0171A, 0172A, 0173A, 0174A</u>) ◀</p>	<p>August 31, 2022</p> <p>December 9, 2022</p> <p>March 17, 2023</p> <p style="text-align: center;"><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>0001A, 0002A: December 11, 2020</del></p> <p><del>0003A: August 12, 2021</del></p> <p><del>0004A: September 22, 2024</del></p> <p><del>0051A, 0052A, 0053A, 0054A, 0071A, 0072A: October 29, 2024</del></p> <p><del>0073A: January 3, 2022</del></p>	<p>CPT® 2024</p>



# CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

			<p>0074A: May 17, 2022</p> <p><del>0081A, 0082A, 0083A: June 17, 2022</del></p> <p>0124A, 91312: August 31, 2022</p> <p>0154A: October 12, 2022</p> <p>0173A: December 8, 2022</p> <p>0174A: March 14, 2023</p> <p>0121A, 0151A, 0171A, 0172A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	
#91307	<p>Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use</p> <p>► (Report 91307 with administration codes 0071A, 0072A, 0073A, 0074A) ◀</p> <p>► (Do not report 91307 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0081A, 0082A, 0083A, 0121A, 0124A, 0151A, 0154A, 0171A, 0172A, 0173A, 0174A) ◀</p>	<p>October 6, 2021</p> <p>January 12, 2022</p> <p>February 1, 2022</p> <p>April 26, 2022</p> <p>June 7, 2022</p> <p>August 31, 2022</p> <p>December 9, 2022</p> <p>March 17, 2023</p> <p><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>0001A, 0002A: December 11, 2020</del></p> <p><del>0003A: August 12, 2021</del></p> <p><del>0004A: September 22, 2021</del></p> <p><del>0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 91307: October 29, 2021</del></p> <p><del>0073A: January 3, 2022</del></p> <p>0074A: May 17, 2022</p> <p><del>0081A, 0082A, 0083A: June 17, 2022</del></p> <p>0124A: August 31, 2022</p> <p>0154A: October 12, 2022</p>	CPT <sup>®</sup> 2023/2024



## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

			<p>0173A: December 8, 2022</p> <p>0174A: March 14, 2023</p> <p>0121A, 0151A, 0171A, 0172A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	
#●91315	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use</p> <p>► (Report 91315 with administration codes <u>0151A</u>, <u>0154A</u>) ◀</p> <p>► (Do not report 91315 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, <u>0121A</u>, <u>0124A</u>, <u>0171A</u>, <u>0172A</u>, <u>0173A</u>, <u>0174A</u>) ◀</p>	<p>August 31, 2022</p> <p>December 9, 2022</p> <p>March 17, 2023</p> <p style="text-align: center;"><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>0001A, 0002A: December 11, 2020</del></p> <p><del>0003A: August 12, 2021</del></p> <p><del>0004A: September 22, 2021</del></p> <p><del>0051A, 0052A, 0053A, 0054A, 0071A, 0072A: October 20, 2021</del></p> <p><del>0073A: January 3, 2022</del></p> <p><del>0074A: May 17, 2022</del></p> <p><del>0081A, 0082A, 0083A: June 17, 2022</del></p> <p>0124A: August 31, 2022</p> <p>0154A, 91315: October 12, 2022</p> <p>0173A: December 8, 2022</p> <p>0174A: March 14, 2023</p> <p>0121A, 0151A, 0171A, 0172A: April 18, 2023</p>	CPT <sup>®</sup> 2024

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

			Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
<p>#<del>91308</del></p>	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use</p> <p>► (Report 91308 with administration codes 0081A, 0082A, 0083A) ◀</p> <p>► (Do not report 91308 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0121A, 0124A, 0151A, 0154A, 0171A, 0172A, 0173A, 0174A) ◀</p>	<p>February 1, 2022</p> <p>April 26, 2022</p> <p>June 7, 2022</p> <p>August 31, 2022</p> <p>December 9, 2022</p> <p>March 17, 2023</p> <p style="text-align: center;"><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>0001A, 0002A: December 11, 2020</del></p> <p><del>0003A: August 12, 2021</del></p> <p><del>0004A: September 22, 2021</del></p> <p><del>0051A, 0052A, 0053A, 0054A, 0071A, 0072A: October 29, 2021</del></p> <p><del>0073A: January 23, 2022</del></p> <p><del>0074A: May 17, 2022</del></p> <p><del>0081A, 0082A, 0083A, 91308: June 17, 2022</del></p> <p>0124A: August 31, 2022</p> <p>0154A: October 12, 2022</p> <p>0173A: December 8, 2022</p> <p>0174A: March 14, 2023</p> <p>0121A, 0151A, 0171A, 0172A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	<p>CPT<sup>®</sup> 2023/2024</p>
<p>#●91317</p>	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2</p>	<p>December 9, 2022</p>	<p><del>0001A, 0002A: December 11, 2020</del></p>	<p>CPT<sup>®</sup> 2024</p>

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	<p>mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use</p> <p>▶ (Report 91317 with administration codes <u>0171A, 0172A, 0173A, 0174A</u>) ◀</p> <p>▶ (Use 91317 <del>only</del> as the third dose in the primary series, with the first two doses reported using 91308, 0081A, 0082A) ◀</p> <p>▶ (Use 91317 as the <del>booster</del> <u>additional</u> dose in the primary series, with the first three doses reported using 91308, 0081A, 0082A, 0083A) ◀</p> <p>▶ (Do not report 91317 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, <u>0121A, 0124A, 0151A, 0154A</u>) ◀</p>	<p><b>New Parenthetical Note Released to AMA Website</b></p> <p>March 17, 2023</p> <p><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>0003A: August 12, 2021</del></p> <p><del>0004A: September 22, 2021</del></p> <p><del>0051A, 0052A, 0053A, 0054A, 0071A, 0072A: October 20, 2021</del></p> <p><del>0073A: January 3, 2022</del></p> <p><del>0074A: May 17, 2022</del></p> <p><del>0081A, 0082A, 0083A: June 17, 2022</del></p> <p>0124A: August 31, 2022</p> <p>0154A: October 12, 2022</p> <p>0173A, 91317: December 8, 2022</p> <p>0174A: March 14, 2023</p> <p>0121A, 0151A, 0171A, 0172A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	
<p>#●91301</p>	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use</p> <p>▶ (Report 91301 with administration codes 0011A, 0012A, 0013A) ◀</p> <p>▶ (Do not report 91301 in conjunction with administration codes 0064A, <u>0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A, 0134A, 0141A, 0142A, 0144A, 0164A</u>) ◀</p>	<p>November 10, 2020</p> <p>August 16, 2021</p> <p><b>New Parenthetical Note Released to AMA Website</b></p> <p>May 19, 2022</p> <p>July 6, 2022</p> <p>August 31, 2022</p> <p>November 16, 2022</p>	<p><del>0011A, 0012A, 01301: December 18, 2020</del></p> <p><del>0013A: August 12, 2021</del></p> <p><del>0064A: October 20, 2021</del></p> <p><del>0094A: March 20, 2022</del></p> <p><del>0091A, 0092A, 0093A, 0111A, 0112A, 0113A:</del></p>	<p>CPT<sup>®</sup> 2022/2023/2024</p>



## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

		<p style="text-align: center;"><b>Revised Parenthetical Note Released to AMA Website</b></p> <p style="text-align: center;">May 1, 2023</p>	<p style="text-align: center;">June 17, 2022</p> <p>0134A (18 years and older): August 31, 2022</p> <p>0134A (12 years through 17 years), 0144A: October 12, 2022</p> <p>0164A: December 8, 2022</p> <p>0141A, 0142A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	
<p>#<del>9</del>91306</p>	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use</p> <p>▶ (Report 91306 with administration code 0064A) ◀</p> <p>▶ (Do not report 91306 in conjunction with administration codes 0011A, 0012A, 0013A, <del>0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A, 0134A, 0141A, 0142A, 0144A, 0164A</del>) ◀</p>	<p>September 3, 2021</p> <p style="text-align: center;"><b>New Parenthetical Note Released to AMA Website</b></p> <p style="text-align: center;">May 19, 2022</p> <p style="text-align: center;">July 6, 2022</p> <p style="text-align: center;">August 31, 2022</p> <p style="text-align: center;">November 16, 2022</p> <p style="text-align: center;"><b>Revised Parenthetical Note Released to AMA Website</b></p> <p style="text-align: center;">May 1, 2023</p>	<p><del>0011A, 0012A: December 18, 2020</del></p> <p><del>0013A: August 12, 2021</del></p> <p><del>0064A, 91306: October 20, 2021</del></p> <p><del>0094A: March 29, 2022</del></p> <p><del>0091A, 0092A, 0093A, 0111A, 0112A, 0113A: June 17, 2022</del></p> <p>0134A (18 years and older): August 31, 2022</p> <p>0134A (12 years through 17 years), 0144A: October 12, 2022</p> <p>0164A: December 8, 2022</p> <p>0141A, 0142A: April 18, 2023</p> <p>Highlighted and stricken codes in the</p>	<p style="text-align: center;">CPT<sup>®</sup> 2023/2024</p>

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

			Effective column are no longer authorized for use in the United States as of April 18, 2023	
<p><del>91313</del> ●91313</p>	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use</p> <p>► (Report 91313 with administration code 0134A) ◀</p> <p>► (Do not report 91313 in conjunction with administration codes 0011A, 0012A, 0013A, 0064A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A, <u>0141A, 0142A, 0144A, 0164A</u>) ◀</p>	<p>August 31, 2022 November 16, 2022</p> <p style="text-align: center;"><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>0011A, 0012A: December 18, 2020</del></p> <p><del>0013A: August 12, 2021</del></p> <p><del>0064A: October 20, 2021</del></p> <p><del>0094A: March 29, 2022</del></p> <p><del>0091A, 0092A, 0093A, 0111A, 0112A, 0113A: June 17, 2022</del></p> <p>0134A and 91313 (18 years and older): August 31, 2022</p> <p>0134A (12 years through 17 years), 0144A, 91313 (12 years through 17 years): October 12, 2022</p> <p>0164A: December 8, 2022</p> <p>0141A, 0142A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	<p>CPT<sup>®</sup> 2024</p>
<p><del>91314</del> ●91314</p>	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use</p> <p>► (Report 91314 with administration codes <u>0141A, 0142A, 0144A</u>) ◀</p> <p>► (Do not report 91314 in conjunction with administration codes 0011A, 0012A, 0013A, 0064A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A, <u>0134A, 0164A</u>) ◀</p>	<p>August 31, 2022 November 16, 2022</p> <p style="text-align: center;"><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>0011A, 0012A: December 18, 2020</del></p> <p><del>0013A: August 12, 2021</del></p> <p><del>0064A: October 20, 2021</del></p> <p><del>0094A: March 29, 2022</del></p>	<p>CPT<sup>®</sup> 2024</p>



## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

			<p><del>0091A, 0092A, 0093A, 0111A, 0112A, 0113A:</del> <del>June 17, 2022</del></p> <p>0134A (12 years through 17 years), 0144A, 91314: October 12, 2022</p> <p>0164A: December 8, 2022</p> <p>0141A, 0142A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	
# <del>91311</del>	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use</p> <p>► (Report 91311 with administration codes 0111A, 0112A, <u>0113A</u>) ◀</p> <p>► (Do not report 91311 in conjunction with administration codes 0011A, 0012A, 0013A, 0064A, <u>0091A, 0092A, 0093A, 0094A, 0134A, 0141A, 0142A, 0144A, 0164A</u>) ◀</p>	<p>May 19, 2022</p> <p>July 6, 2022</p> <p>August 31, 2022</p> <p>November 16, 2022</p> <p style="text-align: center;"><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>0064A: October 20, 2021</del></p> <p><del>0094A: March 29, 2022</del></p> <p><del>0091A, 0092A, 0093A, 0111A, 0112A, 0113A, 91314:</del> <del>June 17, 2022</del></p> <p>0134A (18 years and older): August 31, 2022</p> <p>0134A (12 years through 17 years), 0144A: October 12, 2022</p> <p>0164A: December 8, 2022</p> <p>0141A, 0142A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	<p>CPT<sup>®</sup> 2023/2024</p>



## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

<p>#<del>9</del>91316</p>	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use</p> <p>► (Report 91316 with administration code 0164A) ◀</p> <p>► (Do not report 91316 in conjunction with administration codes 0011A, 0012A, 0013A, 0064A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A, 0134A, <u>0141A, 0142A, 0144A</u>) ◀</p>	<p>November 16, 2022</p> <p style="text-align: center;"><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>0011A, 0012A: December 18, 2020</del></p> <p><del>0013A: August 12, 2021</del></p> <p><del>0064A: October 20, 2021</del></p> <p><del>0094A: March 29, 2022</del></p> <p><del>0091A, 0092A, 0093A, 0111A, 0112A, 0113A: June 17, 2022</del></p> <p>0134A (18 years and older): August 31, 2022</p> <p>0134A (12 years through 17 years), 0144A: October 12, 2022</p> <p>0164A, 91316: December 8, 2022</p> <p>0141A, 0142A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	<p>CPT<sup>®</sup> 2024</p>
<p>#<del>9</del>91309</p>	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use</p> <p>► (Report 91309 with administration codes <u>0091A, 0092A, 0093A, 0094A</u>) ◀</p> <p>► (Do not report 91309 in conjunction with administration codes 0011A, 0012A, 0013A, 0064A, <u>0111A, 0112A, 0113A, 0134A, 0141A, 0142A, 0144A, 0164A</u>) ◀</p>	<p>March 7, 2022</p> <p>May 19, 2022</p> <p>July 6, 2022</p> <p>August 31, 2022</p> <p>November 16, 2022</p> <p style="text-align: center;"><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>May 1, 2023</p>	<p><del>0011A, 0012A: December 18, 2020</del></p> <p><del>0013A: August 12, 2021</del></p> <p><del>0064A: October 20, 2021</del></p> <p><del>0094A, 91309: March 29, 2022</del></p> <p><del>0091A, 0092A, 0093A, 0111A, 0112A, 0113A: June 17, 2022</del></p> <p>0134A (18 years</p>	<p>CPT<sup>®</sup> 2023/2024</p>

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

			and older): August 31, 2022  0134A (12 years through 17 years), 0144A: October 12, 2022  0164A: December 8, 2022  0141A, 0142A: April 18, 2023  Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
#/●91302	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5 mL dosage, for intramuscular use  ▶ (Report 91302 with administration codes 0021A, 0022A) ◀	December 17, 2020	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2022
●91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5 mL dosage, for intramuscular use  ▶ (Report 91303 with administration codes 0031A, 0034A) ◀	January 19, 2021  October 27, 2021	0031A, 91303: February 27, 2021  0034A: October 20, 2021  No longer authorized for use in the United States as of June 1, 2023	CPT <sup>®</sup> 2022/2023
#/●91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use  ▶ (Report 91304 with administration codes 0041A, 0042A, 0044A) ◀	May 4, 2021  July 26, 2022  October 10, 2022	0041A, 0042A, 91304: July 13, 2022  0044A: October 19, 2022	CPT <sup>®</sup> 2022/2023
#/●91310	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use  ▶ (Report 91310 with administration code 0104A) ◀	April 26, 2022	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2023

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

90476	Adenovirus vaccine, type 4, live, for oral use			
96372	<p><b>Hydration, Therapeutic, Prophylactic, Diagnostic Injections and Infusions, and Chemotherapy and Other Highly Complex Drug or Highly Complex Biologic Agent Administration</b></p> <p><b>Therapeutic, Prophylactic, and Diagnostic Injections and Infusions (Excludes Chemotherapy and Other Highly Complex Drug or Highly Complex Biologic Agent Administration)</b></p> <p>Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular</p> <p>► (For administration of vaccines/toxoids, see 90460, 90461, 90471, 90472, 0001A, 0002A, <u>0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A</u>) ◀</p>	<p><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>November 10, 2020</p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>May 4, 2021</p> <p>July 30, 2021</p> <p>August 16, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p> <p>October 27, 2021</p> <p>January 12, 2022</p> <p>February 1, 2022</p> <p>March 7, 2022</p> <p>April 26, 2022</p> <p>May 19, 2022</p> <p>June 7, 2022</p> <p>July 6, 2022</p> <p>August 31, 2022</p> <p>October 10, 2022</p> <p>November 16, 2022</p> <p>December 9, 2022</p> <p>March 17, 2023</p> <p>May 1, 2023</p>	<p><b>Revised Parenthetical Note Effective</b></p> <p><del>0001A, 0002A: December 11, 2020</del></p> <p><del>0011A, 0012A: December 18, 2020</del></p> <p>0031A: February 27, 2021</p> <p><del>0003A, 0013A: August 12, 2021</del></p> <p><del>0004A: September 22, 2021</del></p> <p><del>0034A, 0064A: October 20, 2021</del></p> <p><del>0051A, 0052A, 0053A, 0054A, 0071A, 0072A: October 29, 2021</del></p> <p><del>0073A: January 3, 2022</del></p> <p><del>0094A: March 29, 2022</del></p> <p><del>0074A: May 17, 2022</del></p> <p><del>0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0111A, 0112A, 0113A: June 17, 2022</del></p> <p>0041A, 0042A: July 13, 2022</p> <p>0124A, 0134A (18 years and older): August 31, 2022</p> <p>0134A (12 years through 17 years), 0144A, 0154A: October 12, 2022</p>	<p><b>Revised Parenthetical Note Publication</b></p> <p>CPT<sup>®</sup> 2022/2023/2024</p>

## CPT® Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

			<p>0044A: October 19, 2022</p> <p>0164A, 0173A: December 8, 2022</p> <p>0174A: March 14, 2023</p> <p>0121A, 0141A, 0142A, 0151A, 0171A, 0172A: April 18, 2023</p> <p>Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p> <p>0021A, 0022A, 0104A: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	
	<p><b>Appendix Q</b></p> <p><b>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines</b></p> <p>This table links the individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine product codes (<del>91300-91317, 91316, 91315, 91311, 91310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309</del>) to their associated immunization administration codes (0001A, 0002A, <u>0003A</u>, <u>0004A</u>, 0011A, 0012A, <u>0013A</u>, 0021A, 0022A, 0031A, <u>0034A</u>, 0041A, 0042A, <u>0044A</u>, <u>0051A</u>, <u>0052A</u>, <u>0053A</u>, <u>0054A</u>, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, <u>0134A</u>, <u>0141A</u>, <u>0142A</u>, <u>0144A</u>, <u>0151A</u>, <u>0154A</u>, <u>0164A</u>, <u>0171A</u>, <u>0172A</u>, <u>0173A</u>, <u>0174A</u>), <u>patient age</u>, manufacturer name, vaccine name(s), 10- and 11-digit National Drug Code (NDC) Labeler Product ID, and interval between doses. These codes are also located in the <b>Medicine</b> section of the CPT code set.</p> <p>Additional introductory and instructional information for codes <u>0001A</u>, 0002A, <u>0003A</u>, <u>0004A</u>, 0011A, 0012A, <u>0013A</u>, 0021A, 0022A, 0031A, <u>0034A</u>, 0041A, 0042A, <u>0044A</u>, <u>0051A</u>, <u>0052A</u>, <u>0053A</u>, <u>0054A</u>, 0064A, 0071A, 0072A,</p>	<p><b>New Appendix Q Released to AMA Website</b></p> <p>November 10, 2020</p> <p><b>Revised Appendix Q Released to AMA Website</b></p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>May 4, 2021</p> <p>July 30, 2021</p> <p>August 16, 2021</p> <p>September 3, 2021</p> <p>October 6, 2021</p>	<p><b>Appendix Q Effective</b></p> <p><del>0001A, 0002A, 91300-</del> December 11, 2020</p> <p><del>0011A, 0012A, 91301-</del> December 18, 2020</p> <p>0031A, 91303: February 27, 2021</p> <p><del>0003A, 0013A:</del> August 12, 2021</p> <p><del>0004A:</del> September 22, 2021</p> <p>0034A, <del>0064A, 91306-</del> October 20, 2021</p> <p><del>0051A, 0052A, 0053A, 0054A,</del></p>	<p><b>Appendix Q Publication</b></p> <p>CPT® 2022/2023/2024</p>



## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

<p><u>0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A and 91300-91317, 91316, 91315, 91311, 91310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309</u> can be found in the <b>Immunization Administration for Vaccines/Toxoids</b> and <b>Vaccines, Toxoids</b> guidelines in the <b>Medicine</b> section of the CPT code set.</p>	<p>October 27, 2021          January 12, 2022          February 1, 2022          March 7, 2022          April 26, 2022          May 19, 2022          June 7, 2022          July 6, 2022          August 31, 2022          October 10, 2022          November 16, 2022          December 9, 2022          March 17, 2023          May 1, 2023</p>	<p><del>0071A, 0072A, 91305, 91307, October 29, 2021</del>  <del>0073A, January 3, 2022</del>  <del>0094A, 91309, March 29, 2022</del>  <del>0074A, May 17, 2022</del>  <del>0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0111A, 0112A, 0113A, 91308, 91311, June 17, 2022</del>          0041A, 0042A, 91304:          July 13, 2022          0124A, 0134A (18 years and older):          August 31, 2022          0134A (12 years through 17 years), 0144A, 0154A, 91315:          October 12, 2022          0044A: October 19, 2022          0164A, 0173A, 91316, 91317:          December 8, 2022          0174A: March 14, 2023          0121A, 0141A, 0142A, 0151A, 0171A, 0172A:          April 18, 2023          Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023</p>	
---	---	---	--



# CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

			0021A, 0022A, 0104A, 91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	
--	--	--	---	--



## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

Vaccine Code	Vaccine Administration Code(s)	Patient Age	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
#●91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use	●0001A (1st Dose) ●0002A (2nd Dose) ●0003A (3rd Dose) ●0004A (Booster)	<u>12 years and older</u>	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine/ <u>Comirnaty</u>	59267-1000-1 59267-1000-01	<del>1st Dose to 2nd Dose: 21 Days</del>  <del>2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]): 28 or More Days</del>  <u>Booster-All Dosing: Refer to FDA/CDC Guidance</u>
<del>#●91305</del> <u>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use</u>	<del>#●0051A (1st Dose)</del> <del>#●0052A (2nd Dose)</del> <del>#●0053A (3rd Dose)</del> <del>#●0054A (Booster)</del>	<u>12 years and older</u>	<u>Pfizer, Inc</u>	<u>Pfizer-BioNTech COVID-19 Vaccine/Comirnaty</u>	<u>59267-1025-1</u> <u>59267-1025-01</u> <u>00069-2025-1</u> <u>00069-2025-01</u>	<del>1st Dose to 2nd Dose: 21 Days</del>  <del>2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]): 28 or More Days</del>  <u>Booster-All Dosing: Refer to FDA/CDC Guidance</u>
<del>#●91312</del> <u>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use</u>	<del>#●0121A (1st Dose)</del> <del>#▲●0124A (Booster-Additional Dose)</del>	<u>12 years and older</u>	<u>Pfizer, Inc</u>	<u>Pfizer-BioNTech COVID-19 Bivalent</u>	<u>59267-0304-1</u> <u>59267-0304-01</u> <u>59267-1404-1</u> <u>59267-1404-01</u>	<u>Booster-All Dosing: Refer to FDA/CDC Guidance</u>



## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

Vaccine Code	Vaccine Administration Code(s)	Patient Age	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
# <del>9</del> 91307 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	#●0071A (1st Dose) #●0072A (2nd Dose) #●0073A (3rd Dose) #●0074A (Booster)	5 years through 11 years	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine	59267-1055-1 59267-1055-01	<del>1st Dose to 2nd Dose: 21 Days</del>  <del>2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]) 28 or More Days</del>  <u>Booster-All Dosing: Refer to FDA/CDC Guidance</u>
# <del>9</del> 91315 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	#●0151A (1st Dose) #▲●0154A (Booster-Additional Dose)	5 years through 11 years	Pfizer, Inc	Pfizer-BioNTech COVID-19 Bivalent	59267-0565-1 59267-0565-01	<del>Booster-All Dosing: Refer to FDA/CDC Guidance</del>
# <del>9</del> 91308 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	#●0081A (1st Dose) #●0082A (2nd Dose) #●0083A (3rd Dose)	6 months through 4 years	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine	59267-0078-1 59267-0078-01 59267-0078-4 59267-0078-04	<del>1st Dose to 2nd Dose: 21 Days</del>  <del>2nd Dose to 3rd Dose-All Dosing: Refer to FDA/CDC Guidance</del>





## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

Vaccine Code	Vaccine Administration Code(s)	Patient Age	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
#●91317 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	#●0171A (1st Dose) #●0172A (2nd Dose) #▲●0173A (3rd Dose) #▲●0174A (Booster Additional Dose)	6 months through 4 years	Pfizer, Inc	Pfizer-BioNTech COVID-19 Bivalent	59267-0609-1 59267-0609-01	<u>3<sup>rd</sup> Dose: Refer to FDA/CDC Guidance</u>  <u>Booster All Dosing: Refer to FDA/CDC Guidance</u>
#●91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use	●0011A (1st Dose) ●0012A (2nd Dose) ●0013A (3rd Dose)	<u>1812 years and older</u>	Moderna, Inc	Moderna COVID-19 Vaccine/spikevax	80777-273-10 80777-0273-10 80777-100-11 80777-0100-11	<u>1st Dose to 2nd Dose: 28 Days</u>  <u>2nd Dose to 3rd Dose (CDC recommended population[s] [e.g. immunocompromised]): 28 or More Days</u>  <u>Booster All Dosing: Refer to FDA/CDC Guidance</u>
#▲●91306 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	#●0064A (Booster)	<u>18 years and older</u>	Moderna, Inc	Moderna COVID-19 Vaccine	80777-273-10 80777-0273-10	<u>Refer to FDA/CDC Guidance</u>  <u>All Dosing: Refer to FDA/CDC Guidance</u>
#▲●91313 Severe acute respiratory syndrome coronavirus 2	#▲●0134A (Booster Additional Dose)	<u>1812 years and older</u>	Moderna, Inc	Moderna	80777-282-05 80777-0282-05	



## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

Vaccine Code	Vaccine Administration Code(s)	Patient Age	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
<del>(SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use</del>		<del>12 years through 17 years: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</del>		<del>COVID-19 Vaccine, Bivalent</del>		<del>Booster-Additional Dose: Refer to FDA/CDC Guidance</del>
# <del>9</del> 91314 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	#●0141A (1st Dose) #●0142A (2nd Dose) #▲●0144A (Booster-Additional Dose)	6 months-years through 11 years	Moderna, Inc	Moderna COVID-19 Vaccine, Bivalent	80777-282-05 80777-0282-05	Booster-All Dosing: Refer to FDA/CDC Guidance
# <del>9</del> 91311 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	●0111A (1st Dose) ●0112A (2nd Dose) ●0113A (3rd Dose)	6 months through 5 years	Moderna, Inc	Moderna COVID-19 Vaccine	80777-279-05 80777-0279-05	1st Dose to 2nd Dose: 1 Month  2nd Dose to 3rd Dose (CDC-recommended population[s] [eg, immunocompromised]): 1 Month  All Dosing: Refer to FDA/CDC Guidance

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

Vaccine Code	Vaccine Administration Code(s)	Patient Age	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
# <del>9</del> 91316 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL/10 mcg/0.2 mL dosage, for intramuscular use	<del>▲</del> ●0164A (Booster Additional Dose)	6 months through 5 years	Moderna, Inc	Moderna COVID-19 Vaccine, Bivalent	80777-283-02 80777-0283-02	<del>Booster</del> Additional Dose: Refer to FDA/CDC Guidance
# <del>9</del> 91309 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	●0091A (1st Dose) ●0092A (2nd Dose) ●0093A (3rd Dose)	6 years through 11 years	Moderna, Inc	Moderna COVID-19 Vaccine	80777-275-05 80777-0275-05	1st Dose to 2nd Dose: 1 Month <del>2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]): 1 Month</del> All Dosing: Refer to FDA/CDC Guidance
	# <del>▲</del> ●0094A (Booster)	18 years and older	Moderna, Inc	Moderna COVID-19 Vaccine	80777-275-05 80777-0275-05	<del>Booster</del> : Refer to FDA/CDC Guidance All Dosing: Refer to FDA/CDC Guidance
# <del>9</del> 91302 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5 mL dosage, for intramuscular use	●0021A (1st Dose) ●0022A (2nd Dose)	18 years and older	AstraZeneca, Plc	AstraZeneca COVID-19 Vaccine	0310-1222-10 00310-1222-10	28 Days

## CPT<sup>®</sup> Category I New Immunization\* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

Vaccine Code	Vaccine Administration Code(s)	Patient Age	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
#●91303 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5 mL dosage, for intramuscular use	▲●0031A (Single Dose) ●0034A (Booster)	<u>18 years and older</u>	Janssen	Janssen COVID-19 Vaccine	59676-580-05 59676-0580-05	Not Applicable  <u>Booster: Refer to FDA/CDC Guidance</u>  <u>All Dosing: Refer to FDA/CDC Guidance</u>
#●91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use	●0041A (1st Dose) ●0042A (2nd Dose)	<u>18 years and older</u>	Novavax, Inc	Novavax COVID-19 Vaccine	80631-100-01 80631-1000-01	21 Days
	●0044A (Booster)	<u>18 years and older</u>	<u>Novavax, Inc</u>	<u>Novavax COVID-19 Vaccine</u>	<u>80631-100-01</u> <u>80631-1000-01</u>	<u>Booster: Refer to FDA/CDC Guidance</u>
#●91310 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use	●0104A (Booster)	<u>18 years and older</u>	<u>Sanofi Pasteur</u>	<u>Sanofi Pasteur COVID-19 Vaccine, (Adjuvanted For Booster Immunization)</u>	<u>49281-618-20</u> <u>49281-0618-20</u>	<u>Booster: Refer to FDA/CDC Guidance</u>